medigraphic.com

2018, Number 2

Next >>

Rev Hematol Mex 2018; 19 (2)

The modern treatment of hematological neoplasms or the sad awakening to reality in the clinical practice of a sector of Mexican Hematology: the case of chronic lymphocytic leukemia as a model

Robles-Rodríguez A, Guzmán-Hernández AE, Best-Aguilera CR

Language: Spanish
References: 11
Page: 57-59
PDF size: 235.53 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Zenz T, Mertens D, Döhner H, Stilgenbauer S. Molecular diagnostics in chronic lymphocytic leukemia – Pathogenetic and clinical implications, Leuk Lymph 2009;49:5, 864- 873, DOI: 10.1080/10428190701882955.

  2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinic staging of chronic lymphocytic leukemia. Blood 1975.

  3. Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988;6:7.

  4. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-4088.

  5. Hallek M, Fingerle-Rowson G, Fink AM. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]. Blood 2008;112(11):abstract 325.

  6. Boddy CS, Ma S. Frontline therapy of CLL: Evolving treatment paradigm. Curr Hematol Malig Rep (2018). https://doi.org/10.1007/s11899-018-0438-x

  7. García Vela JA, García Marco JA. Enfermedad mínima residual en la leucemia linfocítica crónica. Med Clin (Barc) 2017. http://dx.doi.org/10.1016/j.medcli.2017.06.067

  8. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 28 November 2013 x Volume 122, Number 23: 3723-3734: doi:10.1182/blood-2013-05-498287.

  9. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-1916.

  10. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-1854.

  11. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-1587.




2020     |     www.medigraphic.com